Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jorveza dose-reduction maintenance trial in eosinophilic oesophagitis
ACTRN12625001296426Phase 4Not yet recruiting
- Sponsor
- Northern Adelaide Local Health Network
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of budesonide in eosinophilic esophagitis (EoE) (2 arms), sponsored by Northern Adelaide Local Health Network. Primary endpoint: Peak eosinophil count at endoscopy and biopsy. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on ACTRN12625001296426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001296426.